Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-16
    E.g., 2018-10-16

Archive Search

2 results
8:45 PM, Apr 12, 2018  |  BC Innovations | Targets & Mechanisms

Meeting the burden

And Apexian Pharmaceuticals Inc. will present data showing interactions between the company’s APEX1 inhibitor, APX3330
and STAT3 or HDAC inhibitors in pancreatic ductal adenocarcinoma (PDAC). APX3330 is in preclinical through Phase …
12:00 AM, Oct 17, 2016  |  BioCentury | Product Development

Yes we PanCAN

NASDAQ:CLVS) Rucaparib (CO-338) PARP-1, PARP-2 Ph II Eisai Co. Ltd. (Tokyo:4523) / ApeX Therapeutics Inc. APX3330